Royal Bank of Canada
DMAC icon

Royal Bank of Canada’s DiaMedica Therapeutics DMAC Stock Holding History

Royal Bank of Canada’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Sell
23,343
-33,545
-59% -$266K ﹤0.01% 4850
2025
Q4 		$453K Buy
56,888
+14,958
+36% +$112K ﹤0.01% 4242
2025
Q3 		$288K Sell
41,930
-35,125
-46% -$191K ﹤0.01% 4852
2025
Q2 		$300K Sell
77,055
-77,976
-50% -$304K ﹤0.01% 4855
2025
Q1 		$588K Buy
155,031
+154,701
+46,879% +$885K ﹤0.01% 3873
2024
Q4 		$2K Sell
330
-475
-59% -$2.24K ﹤0.01% 6700
2024
Q3 		$3K Sell
805
-251
-24% -$927 ﹤0.01% 6587
2024
Q2 		$3K Buy
1,056
+211
+25% +$579 ﹤0.01% 6646
2024
Q1 		$2K Sell
845
-237
-22% -$688 ﹤0.01% 6661
2023
Q4 		$3K Buy
1,082
+277
+34% +$685 ﹤0.01% 6718
2023
Q3 		$2K Sell
805
-79
-9% -$254 ﹤0.01% 6778
2023
Q2 		$3K Buy
884
+79
+10% +$192 ﹤0.01% 6781
2023
Q1 		$1K Hold
805
– – ﹤0.01% 6872
2022
Q4 		$1K Sell
805
-355
-31% -$478 ﹤0.01% 7017
2022
Q3 		$1K Buy
1,160
+355
+44% +$555 ﹤0.01% 7169
2022
Q2 		$2K Hold
805
– – ﹤0.01% 6936
2022
Q1 		$2K Hold
805
– – ﹤0.01% 7469
2021
Q4 		$3K Sell
805
-1,500
-65% -$5.89K ﹤0.01% 7327
2021
Q3 		$9K Hold
2,305
– – ﹤0.01% 6995
2021
Q2 		$10K Buy
2,305
+500
+28% +$4.1K ﹤0.01% 6865
2021
Q1 		$17K Buy
1,805
+959
+113% +$8.96K ﹤0.01% 6510
2020
Q4 		$8K Sell
846
-1,853
-69% -$10.1K ﹤0.01% 6471
2020
Q3 		$11K Buy
2,699
+284
+12% +$1.5K ﹤0.01% 5891
2020
Q2 		$16K Sell
2,415
-384
-14% -$1.71K ﹤0.01% 5672
2020
Q1 		$7K Buy
2,799
+452
+19% +$1.87K ﹤0.01% 5934
2019
Q4 		$11K Buy
2,347
+151
+7% +$470 ﹤0.01% 6098
2019
Q3 		$5K Buy
2,196
+266
+14% +$860 ﹤0.01% 6021
2019
Q2 		$10K Hold
1,930
– – ﹤0.01% 6020
2019
Q1 		$9K Buy
1,930
+1,427
+284% +$5.15K ﹤0.01% 6031
2018
Q4 		$1K Buy
+503
New +$1.58K ﹤0.01% 6558

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's DMAC Position: Q1 2026 in Review

Royal Bank of Canada reduced its DiaMedica Therapeutics (DMAC) stake by 59% in Q1 2026, selling an estimated $266K and leaving 23,343 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #4850.

Royal Bank of Canada first reported a position in DMAC in Q4 2018 and has held it in 30 quarters since. The position peaked at $588K in Q1 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Royal Bank of Canada held 23,343 shares of DiaMedica Therapeutics worth $157K as of Q1 2026.
  • Royal Bank of Canada sold 33,545 DiaMedica Therapeutics shares in Q1 2026, an estimated $266K.
  • DiaMedica Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4850 holding.
  • Royal Bank of Canada first reported a position in DiaMedica Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Royal Bank of Canada's DiaMedica Therapeutics position peaked at $588K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.